Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.59 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.59 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.53 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.53 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
| ▸ | ELANE | P08246 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40184 | 0.98 | HSD17B10 (0.88) | HSD17B10ELANELMNACA1CA2 | |
| Methane SCHEMBL7956977 | 0.96 | HSD17B10 (0.85) | HSD17B10ELANELMNACA1CA2 | |
| SCHEMBL7026750 | 0.96 | HSD17B10 (0.85) | HSD17B10ELANELMNACA1CA2 | |
| Hydrochloric Acid SCHEMBL9636687 | 0.94 | HSD17B10 (0.96) | HSD17B10ELANELMNACA1CA2 | |
| SCHEMBL11028806 | 0.94 | HSD17B10 (0.81) | HSD17B10ELANELMNACA1CA2 | |
| SCHEMBL2886930 | 0.92 | HSD17B10 (1.00) | HSD17B10ELANELMNACA1CA2 | |
| SCHEMBL6310027 | 0.92 | HSD17B10 (0.79) | HSD17B10ELANELMNACA1CA2 | |
| SCHEMBL10455915 | 0.92 | HSD17B10 (0.79) | HSD17B10ELANELMNACA1CA2 | |
| Propane SCHEMBL28675522 | 0.92 | HSD17B10 (0.79) | HSD17B10ELANELMNACA1CA2 | |
| SCHEMBL7794416 | 0.90 | HSD17B10 (0.76) | HSD17B10ELANELMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023120638-A1 | MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM | 東ソー株式会社 | 2023-06-29 | — | — | WO | disclosed |
| WO-2021065549-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, METHOD FOR FORMING PATTERN, AND METHOD FOR PRODUCING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2021-04-08 | — | — | WO | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7153852-B2 | Indole compounds, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-7141627-B2 | Epoxy resin composition | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-11-28 | — | — | US | disclosed |
| EP-1416007-B1 | Epoxy resin composition | DAINIPPON INK & CHEMICALS (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0354355-A1 | Optically active compound and liquid crystal composition | MITSUBISHI RAYON CO., LTD. (JP) | 1990-02-14 | — | — | EP | disclosed |
| US-4876027-A | Optically active composition, mesomorphic compound and liquid crystal device | CANON KABUSHIKI KAISHA (JP) | 1989-10-24 | — | — | US | disclosed |
| EP-0321984-A1 | Mesomorphic compound having beta-hydroxycarboxyl group as chiral source and liquid crystal composition | MITSUBISHI RAYON CO., LTD. (JP) | 1989-06-28 | — | — | EP | disclosed |
| EP-0313379-A2 | Optically active compound having delta-valerolactone ring and liquid crystal composition comprising same | MITSUBISHI RAYON CO., LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
| EP-0299789-A1 | Mesomorphic compound having alkyl beta-hydroxycarboxylate as chiral group and liquid crystal composition containing same | MITSUBISHI RAYON CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
| US-4751018-A | DISCOLORATION INHIBITION | MITSUBISHI RAYON COMPANY LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0255962-A2 | Optically active mesomorphic compound | CANON KABUSHIKI KAISHA (JP) | 1988-02-17 | — | — | EP | disclosed |
| EP-0240184-A2 | Alpha-Methylcinnamic acid ester derivative and liquid crystal composition | MITSUBISHI RAYON CO., LTD. (JP) | 1987-10-07 | — | — | EP | disclosed |
| US-4565780-A | ENZYMATIC HYDROLYSIS OR A P-HYDROXYBENZOYL CHOLINE IN THE PRESENCEOF REDUCED NICOTINAMIDE-ADENINE DINUCLEOTIDE PHOSPHATE; LIVER DISORERS | SHINO-TEST LABORATORY CO., LTD. (JP) | 1986-01-21 | — | — | US | disclosed |
| US-3940407-A | β-Adrenergic blocking agents in the 1,2,3-thiadiazole series | SYNTEX (U.S.A.) INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | IDO1, IDO2, PTGIR | CA2 2810/4885GAA 4667/4885HSP90AA1 4232/4885 |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | CA2 3686/4885GAA 4401/4885HSP90AA1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.